Jim Durgeloh, 59, was desperate to avoid surgery. After a career as a construction contractor and hours of leisure time spent on a motorcycle around his Longview, Wash., home, he was facing an operation to replace his left hip.
Thats pretty invasive, he said, nervous about a surgery that would require being cut open and implanted with an artificial hip; Jims brother had died from complications after a similar operation. In the search for an alternative, he and his wife, Janet, happened upon the website for La Jolla-based StemGenex Medical Group, which touts itself as the worlds first and only Stem Cell Center of Excellence.
But what caught the Durgelohs attention were the words of Rita Alexander, its chief administrative officer and a founder.
Alexander wrote that she had suffered debilitating rheumatoid arthritis until a stem cell treatment sent her into remission. Today it remains my passion to advocate for those diagnosed with debilitating illnesses to have access to cutting edge stem cell treatment, she wrote.
Rita was very inspiring, Janet Durgeloh says.
Durgelohs doctor in Washington was skeptical about the therapy offered by StemGenex. He didnt think it was going to work, Durgeloh says. The therapy isnt approved by the Food and Drug Administration, which says such treatments are not based on scientific evidence and can be unsafe. Then there was the cost: about $15,000, not including airfare. That wasnt covered by Durgelohs insurance, which would have paid for his hip replacement.
But on a recent Wednesday morning, the Durgelohs were at the DoubleTree hotel in Del Mar, where their bill was paid by StemGenex. Durgeloh was still wearing a bandage on his midriff, where a StemGenex doctor had performed liposuction to obtain stem cells that subsequently were reinjected into his body, ostensibly to regenerate his damaged bones and tissues. They were preparing to fly home, infused with the hope communicated by the clinic staff, who seemed very optimistic, Durgeloh told me.
A lawsuit in San Diego federal court suggests that StemGenex may have given the Durgelohs nothing but hope. Three StemGenex patients two with diabetes and one with lupus say they were misled by the medical groups marketing pitch to pay $14,900 each in 2015 and 2016 for therapies that have had no effect.
The lawsuit, which seeks class-action status, claims that StemGenex has made its money by targeting the ill and the elderly with false, fabricated and purposefully misleading claims about patient satisfaction. Selena Moorer, a lupus patient from Florida, and her two co-plaintiffs say StemGenex has no reasonable basis for its marketing claim that the Stem Cell Treatments were effective to treat diseases as advertised. The lawsuit names StemGenex, Alexander and Andre Lallande, the groups chief medical officer, as defendants. The company denies the claims made in the lawsuit.
Durgelohs treatment was typical of the procedures offered as stem cell therapy. He says he received injections directly into his hips, his ailing knees and his back, with whatever was left over suffused into his body via an IV drip.
Whats most important to know is that theres no accepted scientific evidence that treatments using cells from adipose fat tissue layers work.
But as we reported last year, many clinics offering the treatments capitalize on the publics impression that stem cells have become some sort of medical miracle. Dr. Mehmet Oz warned his vast television audience about this misconception in February, when he aired a lengthy undercover investigation of stem cell clinics and called for government regulation. StemGenex wasnt mentioned in the piece.
StemGenex, in its reply to the Moorer lawsuit, asserts that the plaintiffs cannot prove that its representations regarding the efficacy of its stem cell treatments are actually false. The plaintiffs, it continues, do not cite to a single scientific study that disproves [StemGenexs] advertised claims.
StemGenex may not have to prove that in a court of law, but thats not the way federal regulation works. At nearly $15,000 a pop, the companies should have to show a treatment works.
The FDA has been grappling with this very point in pondering how to regulate the burgeoning industry. There are more than 500 clinics offering stem cell treatments in the U.S., according to a survey released last year by stem cell scientist Paul Knoepfler of UC Davis and bioethicist Leigh Turner of the University of Minnesota.
Right now, theres no consensus how these clinics should be regulated.
In 2015, UC San Diego researchers described stem cell treatment as medicines Wild West. As Hermes Taylor-Weiner and Joshua Graff Zivin observed, Because FDA guidelines are ambiguous, stem-cell clinics have in effect been operating without regulation.
The proliferation of the clinics has forced the FDA to take a closer look.
The government agency maintains that using stem cells extracted from a patients fat requires licensing as a drug, device or biological product, which means the clinics have to demonstrate the products are safe and effective, possibly via a clinical trial.
The clinics obviously disagree. Steven Brody, chief scientific officer of StemGenex, testified at an FDA hearing in September that if the FDA took a hands-off approach, this would help our patients have access to stem cell therapies.
Earlier this month, the New England Journal of Medicine reported the devastating outcome for three elderly women injected with fat-derived stem cells directly into their eyeballs by a clinic in Florida as a treatment for macular degeneration. The treatment left the patients totally or mostly blind.
Stem cell clinics typically are cagey about what patients should expect. They neither claim their treatments are effective nor explicitly state that theyre unfounded, Taylor-Weiner and Zivin observed. Their language is intentionally imprecise and exploits the vulnerability of patients with debilitating diseases.
Indeed, a disclaimer on the StemGenex home page states, Stem cell therapy is not FDA approved, and, StemGenex Medical Group and affiliates do not claim that treatment using autologous stem cells are a cure for any condition, disease, or injury.
Thats a striking admission for a treatment costing nearly $15,000 out-of-pocket and might help explain why health insurers shun the treatments.
The emotional video testimonials from patients posted on the StemGenex website carry disclaimers that the results experienced by those patients may not be typical or expected. You should not expect to experience these results.
When I asked Jamie Schubert, a StemGenex spokeswoman, to point me to a scientific study or any other evidence that its treatments work, she replied that anecdotal feedback from patients indicates that their symptoms have improved and their quality of life has increased.
There are other red flags. One of the medical groups physicians, plastic surgeon Scott Sessions, was placed on three years probation by the California Medical Board in February. He was accused of negligence related to cosmetic surgery and other procedures he performed on two patients at an unrelated facility in 2011 and 2013.
Schubert told me Wednesday that Dr. Sessions has informed us that he is in compliance with all requirements of the probationary terms of the medical board. But the very next day, his name, photograph and bio had disappeared from the StemGenex website. Sessions didnt respond to a request for comment.
The same thing happened with the logo of the American Board of Surgery, which had been prominently displayed on the StemGenex site, implying the company had the certification boards seal of approval. After I mentioned to Schubert that a board official told me that display was a complete misuse of our logo, it vanished. Schubert called it an error.
Peoples health needs are not suitable for unregulated Wild West experimentation, and anecdotal feedback isnt proof that cutting edge treatments are safe and effective. The course couldnt be clearer for the FDA and state medical regulators across the country: If these stem cell clinics are endangering their customers health and draining their pocketbooks for quack remedies, shut them down.
Keep up to date with Michael Hiltzik. Follow @hiltzikm on Twitter, see his Facebook page, or email michael.hiltzik@latimes.com.
Return to Michael Hiltzik's blog.
Original post:
The stem cell therapies offered by this La Jolla clinic aren't FDA ... - Los Angeles Times
- The therapeutic potential of stem cells - PMC - December 19th, 2024
- Researchers find success with stem cell therapy in mice model of ... - December 19th, 2024
- Advancing the Battle against Cystic Fibrosis: Stem Cell and Gene ... - December 19th, 2024
- Study finds stem cell therapy is safe and may benefit people with ... - October 22nd, 2024
- Stem Cell Therapy Market Size to Hit USD 48.89 Billion by 2033 - GlobeNewswire - October 22nd, 2024
- Eves dream to walk: Family raising vital funds for two-year-olds stem cell therapy - Her.ie - October 22nd, 2024
- Stem cell therapies for chronic obstructive pulmonary disease ... - September 21st, 2024
- Magellan Stem Cells welcomes $7 million federal government grant - September 21st, 2024
- Stem Cell Therapy Research: Creative Biolabs Advances iPSC-Derived Macrophage Solutions - openPR - September 21st, 2024
- Stem Cell Therapy Market Dynamics: Size, Share, and Growth - openPR - September 21st, 2024
- Stem cells: Therapy, controversy, and research - Medical News Today - September 4th, 2024
- Stem cell-based therapy for human diseases - PMC - September 4th, 2024
- Bone marrow mesenchymal stem cells in treatment of peripheral nerve ... - September 4th, 2024
- Stem Cell Therapy Mexico: R3 Stem Cell Unveils Innovative and Affordable Non-Invasive Solutions - openPR - September 4th, 2024
- 'Didn't know this would be possible': Autistic teen's mom on stem cell therapy benefits - WZTV - May 5th, 2024
- Putting Stem Cell-Based Therapies in Context | National Institutes of ... - April 8th, 2024
- Eggs from men, sperm from women: Stem cell therapy may just turn reproduction upside down! - The Economic Times - January 17th, 2024
- Stem Cell Therapy: From Idea to Clinical Practice - PMC - December 13th, 2023
- Current state of stem cell-based therapies: an overview - PMC - November 18th, 2023
- Stem Cell Therapy Is It Right for You? Cleveland Clinic - January 31st, 2023
- Stem Cell Therapy | Mellon Center Approach | Cleveland Clinic - January 31st, 2023
- Stem Cell Therapy for Parkinson's: Current Developments - Healthline - December 3rd, 2022
- Canine Stem Cell Therapy Market Size 2022 with a CAGR of % Market Share, prime companies report covers, world business Trends, Statistics, Definition,... - June 16th, 2022
- Global Rheumatoid Arthritis Stem Cell Therapy Market 2022 Swot Analysis by Top Key Vendors, Demand And Forecast Research to 2028 Designer Women -... - June 16th, 2022
- Sutton boy pledges to raise money to help his brother with autism go to America for stem cell therapy - Mansfield and Ashfield Chad - June 16th, 2022
- Japan's five hottest biotech companies in healthcare - Labiotech.eu - June 16th, 2022
- Hemostemix Announces the Incorporation of PreCerv Inc. And a Global Field of Use License to NCP-01 - Yahoo Finance - June 16th, 2022
- Stem cell therapy shows promise in aiding equine wound healing - Horsetalk.co.nz - Horsetalk - April 2nd, 2022
- Rheumatoid Arthritis Stem Cell Therapy Market Assessment, With Major Top Companies Analysis, Geographic Analysis, Growing Opportunities Data By... - April 2nd, 2022
- Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual Meeting - Yahoo... - April 2nd, 2022
- Talaris therapy ends need for immune drugs in transplant patients - - pharmaphorum - November 7th, 2021
- Safety of Stem Cell Therapy for Chronic Knee Pain Confirmed in New Study - SciTechDaily - August 4th, 2021
- Multiple myeloma stem cell transplant: What happens and more? - Medical News Today - August 4th, 2021
- Animal Stem Cell Therapy Market Research 2021-2027 With Medivet Biologics LLC, VETSTEM BIOPHARMA, J-ARM, US Stem Cell The Manomet Current - The... - August 4th, 2021
- Global Stem Cell Therapy Market to witness exponential proliferation during 2020-2026 The Manomet Current - The Manomet Current - August 4th, 2021
- FDA gives speedy review to Bayer's Parkinson's stem cell therapy - - pharmaphorum - July 21st, 2021
- Stem Cell Therapy Market Analysis of Key Players, End User, Demand and Consumption By 2026 26 Sports - 2x6 Sports - July 21st, 2021
- NanoString Launches nCounter Stem Cell Characterization Panel to Advance the Development of Stem Cell Therapy - Business Wire - June 24th, 2021
- Adipose Tissue Derived Stem Cell Therapy Market New Innovation and Perception 2028 AlloCure, Antria, Celgene, Cellleris SA, Corestem, Intrexon,... - June 24th, 2021
- Jasper Therapeutics and Aruvant Announce Research Collaboration to Study JSP191, an Antibody-Based Conditioning Agent, with ARU-1801, a Novel Gene... - June 24th, 2021
- Global Nerve Repair and Regeneration Devices Market to Reach $11. 8 Billion by 2026 - GlobeNewswire - June 24th, 2021
- Controversial Stem Cell Therapy Has Helped Repair Injured Spinal Cords in 13 Patients - ScienceAlert - March 3rd, 2021
- Cynata tests wound dressing tech for stem cell therapy delivery - The West Australian - March 3rd, 2021
- Stem Cell Injections Could Treat Spinal Cord Injuries | IE - Interesting Engineering - March 3rd, 2021
- NSAIDs to Treat Arthritic Canines Through 2028; Stem Cell Therapies to Invigorate Canine Arthritis T - PharmiWeb.com - March 3rd, 2021
- Overview of stem cells therapy in amyotrophic lateral sclerosis - DocWire News - March 3rd, 2021
- We have a hint it may be possible: Controversial stem cell therapy repaired injured spinal cords in 13 patients - RT - March 3rd, 2021
- Global Stem Cell Therapy Market 2021- Regional Analysis(Consumption, Revenue, Market Share and Growth Rate) and Forecast Till 2027 NeighborWebSJ -... - March 3rd, 2021
- Global Animal Stem Cell Therapy Market 2020 2025 Research Report Segment Outlook, Growth Potentials and Analysis of COVID-19 Worldwide Outbreak KSU... - March 3rd, 2021
- Animal Stem Cell Therapy Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The Bisouv Network - The... - March 3rd, 2021
- Projected Stem Cell Therapy Market Growth After Coronavirus COVID-19 Outbrek Analysis and Forecast (2020-2027) The Bisouv Network - The Bisouv... - March 3rd, 2021
- Stem Cell and PRP Injection for Knee Osteoporosis Pain and Injury Using US Image Guidance - Magazine of Santa Clarita - March 3rd, 2021
- Animal Stem Cell Therapy Market Potential Growth, Share and Demand Analysis of Key Players MediVet Biologic, VETSTEM BIOPHARMA, J-ARM, Celavet NY... - March 3rd, 2021
- Musculoskeletal Disorder Stem Cell Therapy Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The... - March 3rd, 2021
- Exclusive Insights on Stem Cell Therapy for Multiple Sclerosis Market 2021-2026: Latest Trends, Drivers, Strategies and Competitive Landscape The... - March 3rd, 2021
- Stem Cell Therapy Market By Treatment,Application,End Users And Geography Forecast To 2027 The Bisouv Network - The Bisouv Network - March 3rd, 2021
- 10 Best Clinics for Stem Cell Therapy in Thailand [2021 ... - February 14th, 2021
- Therapeutic Solutions International Acquires Stem Cell Therapy That Successfully Completed FDA Double Blind Placebo Controlled Efficacy Study for Lung... - February 14th, 2021
- Outlook on the Cell Therapy Global Market to 2027 - Opportunity Analysis and Industry Forecasts - Yahoo Finance - February 14th, 2021
- Global Stem Cell Therapy Market Set to Reach USD 214.5 Million by 2024 - The Courier - February 14th, 2021
- Magenta Therapeutics to Present Additional Data from Phase 1 MGTA-145 Stem Cell Mobilization Program and Preclinical Updates on Targeting Conditioning... - February 14th, 2021
- Stem Cell Therapy Market Revenue, Key Players, Supply-Demand, Investment Feasibility and Forecast By 2029: Osiris Therapeutics, NuVasive, Chiesi... - February 14th, 2021
- Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Tendencies, Revenue Forecast and Interesting Opportunities from 2020 to 2025 FLA... - February 14th, 2021
- Dancing on Ice's Colin Jackson to get stem cell op as he's got 'knees of 85-year-old' - Mirror Online - February 1st, 2021
- Stem Cell Therapy Market Size to Reach USD 5,040 Million by 2028 | Rising Public-Private Investments and Developing Regulatory Framework for Stem Cell... - January 31st, 2021
- ProgenCell - Stem Cell Therapies offers an updated Stem Cell Therapy for Anti Aging Protocol - PR Web - January 31st, 2021
- Stem Cell Therapy Market 2021: Global Key Players, Trends, Share, Industry Size, Segmentation, Forecast To 2027 KSU | The Sentinel Newspaper - KSU |... - January 31st, 2021
- ClearPoint Neuro, Inc. Announces Expansion of Pre-Clinical and Translational Development Team to Support Gene and Stem Cell Therapy Partners -... - January 31st, 2021
- Stem Cell Therapy for Diabetes and Related Conditions Market Size |Incredible Possibilities and Growth Analysis and Forecast To 2025 - AlgosOnline - January 31st, 2021
- Stem Cell Therapy Market 2021 Industry Size, Trends, Global Growth, Insights And Forecast Research Report 2026 NeighborWebSJ - NeighborWebSJ - January 31st, 2021
- Animal Stem Cell Therapy Market to witness high growth in near future - Fractovia News - January 31st, 2021
- Regenerative medicine is advancing health care in diverse ways - Hometown Focus - January 23rd, 2021
- Hemostemix Announces the Bread Contract with the Department of Foreign Affairs, Trade & Development Canada - BioSpace - January 23rd, 2021
- Stem Cell Therapy Market Size, Growth Opportunities, Trends, Key Players and Forecast to 2027 - The Courier - January 23rd, 2021
- Animal Stem Cell Therapy Market Size, Business Growth Tactics, Future Strategies, Competitive Outlook and Forecast to 2027 Jumbo News - Jumbo News - January 23rd, 2021
- How Will Global Stem Cell Therapy Market React from 2021 Onwards? - The Courier - January 23rd, 2021
- Impact of COVID-19 on Canine Stem Cell Therapy Market by 2027 |Aratana Therapeutics, Okyanos, Magellan Stem Cells, Stem Cell Vet, VetStem Biopharma -... - January 23rd, 2021
- Impact of COVID-19 on Canine Stem Cell Therapy Market 2021 | Size, Growth, Demand, Opportunities & Forecast To 2027 | VETSTEM BIOPHARMA, Cell... - January 23rd, 2021
- Global Animal Stem Cell Therapy Market Size| Share| Trends and Analysis | Industry Growth Insight By 2025 Globalmarketers.biz Jumbo News - Jumbo... - January 23rd, 2021
- Impacts of COVID 19 on Stem Cell Therapy Market 2021 Size, Demand, Opportunities & Forecast To 2026 - NeighborWebSJ - January 23rd, 2021